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Background: Deregulation of receptor tyrosine kinases (RTK) contributes to the initiation and progression of
intestinal-derived epithelial cancers, including colorectal cancer (CRC). However, the roles of the proximal signaling
molecules engaged by RTKs in different oncogenic functions of CRC remain unclear.
Methods: Herein, the functional impact of expressing variant forms of the oncogenic Met receptor (Tpr-Met) that
selectively recruit the adaptor proteins Grb2 or Shc was investigated in a model derived from normal intestinal
epithelial cells (IEC-6). An RNA interference (RNAi) approach was used to define the requirement of Grb2 or Shc in
Tpr-Met-transformed IEC-6 cells. Since Grb2 and Shc couple RTKs to the activation of the Ras/MEK/Erk and PI3K/
Akt pathways, Erk and Akt phosphorylation/activation states were monitored in transformed IEC-6 cells, and a
pharmacological approach was employed to provide insights into the roles of these pathways in oncogenic
processes evoked by activated Met, and downstream of Grb2 and Shc.
Results: We show, for the first time, that constitutive activation of either Grb2 or Shc signals in IEC-6 cells,
promotes morphological transformation associated with down-regulation of E-cadherin, as well as increased cell
growth, loss of growth contact inhibition, anchorage-independent growth, and resistance to serum deprivation
and anoikis. Oncogenic activation of Met was revealed to induce morphological transformation, E-cadherin
down-regulation, and protection against anoikis by mechanisms dependent on Grb2, while Shc was shown to
be partly required for enhanced cell growth. The coupling of activated Met to the Ras/MEK/Erk and PI3K/Akt
pathways, and the sustained engagement of Grb2 or Shc in IECs, was shown to trigger negative feedback,
limiting the extent of activation of these pathways. Nonetheless, morphological alterations and E-cadherin
down-regulation induced by the oncogenic Tpr-Met, and by Grb2 or Shc signals, were blocked by MEK, but not
PI3K, inhibitors while the enhanced growth and resistance to anoikis induced by Tpr-Met were nearly abolished
by co-treatment with both inhibitors.
Conclusion: Overall, these results identify Grb2 and Shc as central signaling effectors of Met-driven progression
of intestinal epithelial-derived cancers. Notably, they suggest that Grb2 may represent a promising target for the
design of novel CRC therapies.
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When activated, cell surface growth factor receptor tyrosine
kinases (RTK) become phosphorylated at a number of tyro-
sine (Tyr) residues. Many of those located within the cyto-
plasmic tail of the receptor create binding sites for proteins
containing Src homology 2 (SH2) and phosphotyrosine-
binding (PTB) domains, which recognize phospho-Tyr resi-
dues within the context of specific adjacent amino acids.
Proteins recruited to RTKs include enzymes, such as
phospholipase Cγ (PLCγ) and phosphatidylinositol 3-kinase
(PI3K); and adaptor proteins, including growth factor
receptor-bound protein-2 (Grb2) and Src-homology colla-
gen (Shc) proteins. These latter proteins contain multiple
protein-protein interactions motifs. The resulting complex
relays and amplifies an exquisitely fine-tuned regulation
of multiple downstream signaling events, which de-
pending on cellular context, mediate specific biological
responses (reviewed in [1]). This regulation is perturbed
in cancers, including those of intestinal epithelial cell
(IEC) origin such as colorectal cancer (CRC).
Deregulation of RTKs in CRC commonly involves the
over-expression of the receptor and/or its ligand. As il-
lustrated by the Met/hepatocyte growth factor (HGF)
and epidermal growth factor receptor (EGFR) signaling
axis, this dysregulation often takes place at the earliest
stages of the disease and it is observed in virtually all
metastatic CRC (reviewed in [2-4]). Ligand or receptor
deregulation may result in a lower threshold for growth
factor stimulation, autocrine/paracrine ligand-receptor
activation loops, and even ligand-independent constitu-
tive receptor activation. Regardless of the mechanisms of
RTK oncogenic activation, the outcome is the loss of the
normally fine-tuned regulation of downstream signaling,
which may ultimately contribute to the acquisition of
cancer properties. Notably, its has been shown that the
expression of constitutively activated forms of the Met
receptor in non-transformed IECs promoted morpho-
logical transformation; enhanced proliferation rate; in-
duced loss of both growth contact inhibition and
anchorage-dependent growth; and increased in vivo an-
giogenic, tumorigenic, and metastatic capacities [5,6].
Studies performed predominantly in fibroblast and
breast cancer cell models have revealed that Grb2 and
Shc adaptor proteins are among the signaling proteins
that, upon recruitment by activated RTKs, mediate
events directly linked to the initiation and progression of
cancer [7-12]. Many RTKs interact directly with Grb2,
some rely on Shc family adaptors to recruit Grb2, and
others do both [1]. While direct Grb2/RTK interactions
involve binding of the Grb2 SH2 domain to pYXNX mo-
tifs, Shc proteins interact with RTKs primarily through
the binding of their N-terminal PTB domain to NPXpY
motifs. The latter results in phosphorylation of Tyr resi-
dues within the Shc central collagen-homology domain1 (CH1). These phosphorylated tyrosine residues consti-
tute consensus-binding sites for the Grb2 SH2 domain,
thus allowing Shc to engage Grb2-driven signaling path-
ways (reviewed in [13]). The best-characterized role of
the two adaptor proteins, Grb2 and Shc, is to link RTKs
to the activation of the Ras/Raf/MEK/Erk mitogenic
(Ras/MAPK) pathway. The constitutive association of
the N-terminal Grb2 SH3 domain with the Ras guanine
nucleotide exchange factor, Son of Sevenless (SOS) con-
stitutes one component of this connection [1]. Inter-
action of the C-terminal Grb2 SH3 domain with Grb2-
associated binding (Gab) scaffold protein family mem-
bers couples RTKs to the PI3K/Akt survival pathway
and to the Ras/MAPK cascade by an alternate route
[14]. As such, the recruitment of Grb2 or Shc to RTKs
has been shown to promote biologically redundant pro-
cesses [7,8,15,16]. However, Shc proteins interact with
diverse signaling molecules in addition to Grb2, thereby
engage Grb2-independent pathways and biological func-
tions [9-13,17-19].
Although the deregulation of RTKs is widely consid-
ered to be a major determinant in the progression of
CRC, the specific contributions of the proximal signaling
molecules engaged by these receptors in CRC remain
virtually unexplored. Herein, we report the exploitation
of well-characterized adaptor-specific RTK docking vari-
ants derived from the oncogenic Met receptor, Tpr-Met
[8,9,15,16,20], with shRNA and pharmacological interfer-
ence approaches to define, for the first time, the cancer
properties associated with early neoplastic transform-
ation of IECs, induced upon oncogenic mediated activa-
tion of either Grb2 or Shc signaling.
Methods
Antibodies and reagents
The Met polyclonal antibody, kindly provided by Dr.
Morag Park (McGill University, Montreal, QC, Canada),
was raised against an epitope in the C-terminal region
of human Met, distinct from those altered in the vari-
ants (Additional file 1) [8,21]. The Phospho-Tyr (p-Tyr100),
phospho-Akt (Ser473), and phospho-Erk1/2 (p44/42MAPK,
Thr202/Tyr204) antibodies were obtained from Cell Signal-
ing Technology (Danvers, MA, USA). The pan-Shc and
phospho-Tyr Shc (Tyr239/240) antibodies, that recognize
the p66, p52, and p46 isoforms of ShcA, and the Erk2 anti-
body were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). The α-tubulin and β-actin antibodies were
from Sigma-Aldrich Canada Ltd (Oakville, ON, Canada).
The Grb2 and E-cadherin antibodies were purchased from
BD Transduction Labs (Lexington, KY, USA). The MEK1/2
and PI3K inhibitors, U0126 and LY294002, were purchased
from Cell Signaling Technology, while the MEK1/2 inhibi-
tors AZD6244 and PD184352 were obtained from Selleck
Chemicals (Houston, TX, USA).
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As depicted in Additional file 1, the RTK-derived dock-
ing oncoproteins consist of an oncogenic form of the
Met receptor, Tpr-Met, in which the multi-substrate
binding region is replaced with a motif selective for the
recruitment of a single signaling protein, found in other
RTKs [8]. The Grb2-specific Tpr-Met variant (TM-Grb2)
contains the Grb2 binding site derived from EGFR. Dock-
ing variants specific for the recruitment of Shc include ei-
ther the high affinity Shc binding motif from the TrkA
receptor (TM-Shc1), or the lower affinity motif from EGFR
(TM-Shc2). The generation of these specific docking Tpr-
Met variants, and their insertion into the pLXSN retroviral
expression vector were previously described [8]. For stable
silencing of Grb2 and Shc in cells, a short hairpin RNA
(shRNA) lentiviral vector-based approach was used. The
design of the pLenti6-U6 construct for the stable transduc-
tion of shRNAs and the blasticidin S resistance gene has
been described previously [22]. Clontech shRNA Sequence
Designer tool was used to create an shRNA containing nu-
cleotide sequences that target rat Grb2 mRNA [23], the
three ShcA isoforms [24], or a non-targeting control se-
quence [shGrb2 (NM_030846): 5′-GATGTACAGCACTT




Normal rat intestinal epithelial crypt cells, IEC-6, provided
by Dr. A. Quaroni (Cornell University, Ithaca, NY), were
maintained in DMEM (Wisent, St-Bruno, QC, Canada)
containing 10% fetal bovine serum (FBS, Life Technolo-
gies, Burlington, ON, Canada) and 50 μg/mL gentamicin
(Wisent). The IEC-6 cells were validated as non-
transformed, and displaying normal features including an
epithelioid morphology with sparse microvilli and E-
cadherin cell-cell interactions, and a rate of cell division
estimated by growth curve analysis that is typical of nor-
mal undifferentiated IECs [5,22,25]. Stable populations of
IEC-6 cells expressing TM-Grb2, -Shc1, or -Shc2 (TM-
Grb2-IEC-6, TM-Shc1-IEC-6, and TM-Shc2-IEC-6 cells,
respectively) were expanded, following retroviral infection,
from a pool of at least 50 neomycin-resistant colonies, as
described for the generation of IEC-6 cells transformed
with unmodified Tpr-Met (Tpr-Met-IEC-6 cells) [5]. For
each experiment, populations of TM-Grb2-IEC-6, TM-
Shc1-IEC-6, or TM-Shc2-IEC-6 cells were compared
with the previously characterized sham-infected IEC-6
(Control-IEC-6) and Tpr-Met-IEC-6 cells [5], each having
been passaged a comparable number of times (11–25 ± 2).
The binding specificity of these Tpr-Met variants was ex-
tensively validated in earlier studies [8,9,15,16,20,26], and
further confirmed in IEC-6 cells (Additional file 1). Stableknockdown of Grb2 or Shc expression in Tpr-Met-IEC-6
cells was achieved by lentiviral-mediated transduction of
appropriate shRNAs. Production of replication-deficient
lentiviruses in HEK 293 T cells and infection of Tpr-Met-
IEC-6 cells were performed as previously described [22].
Stable populations of Tpr-Met-IEC-6 cells expressing the
shRNA against Grb2 or ShcA (TM-shGrb2 or TM-shShc
cells) were selected, and thereafter maintained with blasti-
cidin S HCl (5 μg/mL). A control Tpr-Met-IEC-6 cell
population expressing a non-targeting shRNA was like-
wise generated (TM-shCTRL).
Immunoprecipitation and immunoblotting
Total cell lysate (TCL) preparation, SDS-PAGE, immuno-
precipitation (IP), and immunoblot (IB) analysis methods
have previously been described [8,9]. Primary antibodies
were used at a concentration of 1:1000, with the exception
of Akt and P-Akt (1:500), Erk2 (1:5000), P-Erk (1:2500),
E-cadherin (1:5000), and α-tubulin and β-actin (1:10000).
Secondary antibodies were used at a concentration of
1:10000. Proteins were visualized by enhanced chemilumin-
escence (ECL, GE Healthcare, Baie d’Urfé, QC, Canada).
Unless otherwise indicated, biochemical analyses were per-
formed at least three times with independent lysate prepa-
rations from cells that had been serum-starved overnight.
Semi-quantitative and quantitative RT-PCR
Total RNA from serum-starved cells was extracted using
TRIzol (Life Technologies) or RiboZol™ RNA Extraction
Reagent (Amresco, Solon, OH), following the manufac-
turer’s protocols. The RNA integrity was assessed with an
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA) and quantitation was performed using a Nano-
drop spectrometer (Thermo Fisher). Reverse transcription
was performed on DNase I-treated RNA (Amplification
grade, Life Technologies) with Omniscript Reverse Tran-
scriptase (Qiagen). Semi-quantitative PCR reactions were
carried out using TOPTaq (Qiagen), according to the
manufacturer’s protocol. Resulting PCR products were
then analyzed on a 2% agarose gel. Quantitative real-time
PCR analyses were performed by the RNomics Platform at
the Université de Sherbrooke (Sherbrooke, QC, Canada).
The sequence of the primers used is listed in Additional
file 2.
Cell-count, focus formation, soft agar growth, and anoikis
assays
For cell-count assays, cells were seeded at a density of
2.5 × 104/well in 6-well plates, and then counted daily.
For focus formation assays, 200 cells of the experimental
populations were seeded in each well of 6-well plates,
with 5 × 105 parental IEC-6 cells forming a monolayer
in each. After 10–15 days, the foci were photographed,
fixed with 10% formalin buffer and stained with Giemsa
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with 5000 cells per well, embedded in Noble Agar
(Difco, BD Transduction Labs, Lexington, KY, USA).
Colonies present after approximately two weeks were
photographed and counted. For anoikis assays, cells were
seeded in serum-free DMEM (or Opti-MEM) at a dens-
ity of 1.25 × 105 cells/well in 24-well plates that were
pre-coated (or not) with polyHEMA [poly-(2-hydro-
xyethyl methacrylate); Sigma]. After 18 hours, cell viabil-
ity was determined by XTT assays [27]. The proportion
of viable cells in polyHEMA-coated wells (suspension),
relative to those seeded in non-coated wells (adherent), was
calculated. Growth curves and bar graphs were generated
using Prism v6.0c (GraphPad software, San Diego, CA,
USA). Unless otherwise indicated, results are expressed as
the mean ± S.E.M. from three independent experiments,
each performed in triplicate. Statistical significance was de-
termined by ANOVA analysis (* indicates a p-value < 0.05;
**, p < 0.01; ***, p < 0.001; and ****, p < 0.0001).Ethics statement
The research carried out did not involve any human
subjects.Results
Oncogenic engagement of Grb2 or Shc signaling
promotes morphological transformation in normal IECs
and reduces E-cadherin expression
In contrast with many other RTKs, the ability of the Met
receptor to recruit signaling proteins, and thus its bio-
logical activities, is dependent on two phospho-Tyr resi-
dues located within its C-terminus (Y1349/Y1356 in
Met; Y482/Y489 in Tpr-Met [28-30]). This unique char-
acteristic has been exploited to generate Met receptor
variants capable of binding exclusively to a single RTK-
proximal signaling protein [8]. These well-characterized
docking-specific Met variants consist of the cytosolic
oncogenic form of the Met receptor, Tpr-Met, in which
the multi-substrate binding region has been replaced
with a motif selective for the recruitment of a single sig-
naling protein, found in other RTKs (Additional file 1
and [8]). To determine whether the selective oncogenic
engagement of either the Grb2 or the Shc adaptor pro-
tein was sufficient to induce transformation of IECs, we
generated populations of IEC-6 cells [25] expressing
Tpr-Met variants that specifically bind to either the
Grb2 (TM-Grb2-IEC-6 cells) or Shc (TM-Shc1-IEC-6
and TM-Shc2-IEC-6 cells, respectively) adaptor proteins,
through retroviral infection. For each experiment, these
cells were compared with the previously characterized
untransformed sham-infected IEC-6 (Control-IEC-6)
cells or those transformed by unmodified Tpr-Met (Tpr-
Met-IEC-6) [5].TM-Grb2-IEC-6, TM-Shc1-IEC-6, and TM-Shc2-IEC-6
cells were morphologically transformed to a similar extent
relative to Control-IEC-6 cells, which grew in colonies and
displayed typical normal epithelioid morphology (Figure 1A).
Morphological changes induced in the TM-Grb2-IEC-6,
TM-Shc1-IEC-6, and TM-Shc2-IEC-6 cells include an
apparent breakdown of cell-cell contacts, cell dispersal, the
acquisition of a fibroblast-like spindle-shaped morphology,
and a more refractile appearance than the Control-IEC-6
cells. Cells expressing the Grb2 and Shc docking-specific
oncoproteins also displayed many cell membrane protru-
sions typical of lamellipodia and invadopodia-like struc-
tures. The Tpr-Met variants exhibited comparable levels of
Tyr phosphorylation in IEC-6 cells, relative to their expres-
sion levels (Figure 1A). They also demonstrated the pre-
dicted binding selectivity [8,9,15,16,20] (Additional file 1).
Since such morphological changes in epithelial cells
are typically associated with down-regulation of E-
cadherin, immunoblot (IB) analysis of the E-cadherin
protein levels were performed [31]. Consistent with the
previous characterization of Tpr-Met-IEC-6 cells [5],
also presented herein, oncogenic activation of Grb2- and
especially Shc-specific signals led to a dramatic decrease
in E-cadherin protein levels relative to the Control-IEC-
6 cells (Figure 1B). Likewise, a marked reduction in E-
cadherin (Cdh1) mRNA levels was observed in these
cells, as determined by semi-quantitative and quantitative
real-time RT–PCR analyses (Figure 1C and D). Analysis of
the expression profiles of E-cadherin transcriptional re-
pressors in these IECs suggests that a combined up-
regulation of Snail2, Twist1, or Twist2, but not of Snail1
or Zeb1, may partly account for the E-cadherin repression
induced by oncogenic Met-dependent signaling, including
that one driven by Grb2 and Shc signals (Additional file 2).
Overall, these results demonstrate that oncogenic activa-
tion of Grb2- and Shc-dependent signaling pathways, such
as those activated by Tpr-Met, is sufficient to induce an
epithelial-mesenchymal morphological-like transformation
in normal IECs.
Oncogenic engagement of Grb2 or Shc signaling enhances
cell growth and loss of contact inhibition in IECs
We next tested the oncogenic growth characteristics of
IEC-6 cells transformed by the Tpr-Met variants. First,
cell-counting assays were performed to determine the
growth rate of each cell population. The TM-Grb2-IEC-
6, TM-Shc1-IEC-6, and TM-Shc2-IEC-6 cells displayed
more rapid growth than Control-IEC-6 cells, albeit to a
lesser extent than Tpr-Met-IEC-6 cells (Figure 2A). Not-
ably, TM-Shc1-IEC-6 cells exhibited accelerated growth
relative to TM-Grb2-IEC-6 and TM-Shc2-IEC-6 cells,
between which the doubling time did not differ signifi-
cantly. The enhanced growth promoting activity of the
TM-Shc1 relative to the TM-Shc2 correlates with the
Figure 1 TM-Grb2, TM-Shc1 and TM-Shc2 oncoproteins promote morphological transformation and E-cadherin down-regulation in
IEC-6 cells. (A) Photographs show the typical morphology of IEC-6 cells expressing, or not (Control), the docking-specific TM-Grb2, TM-Shc1 or
TM-Shc2, or the oncogenic Met receptor, Tpr-Met. Expression and phosphorylation levels of these oncoproteins in IEC-6 cell lysates were assessed
by immunoblot (IB) analyses following immunoprecipitation (IP) with a Met antibody. (B) E-cadherin protein levels were determined by IB analyses of
total cell lysate (TCL) prepared from the indicated serum-starved cells. Tubulin protein levels provide a loading control. (C) E-cadherin mRNA expression
(Cdh1) was evaluated by semi-quantitative RT-PCR assays performed with total RNA prepared from the indicated serum-starved cells. The analyses were
carried out with two sets of primers designed to amplify distinct regions of the rat Cdh1 mRNA. The mRNA encoding for the S18 ribosomal
protein is shown as a loading control. Parallel PCR reactions without the RT enzyme indicate that the amplified products did not arise from
genomic DNA contamination. (D) Relative mRNA expression levels of Cdh1 were analyzed by quantitative real-time RT-PCR. These assays were
carried out with the same RNA samples and sets of Cdh1 primers. The bar graph shows the mean ± S.E.M. fold-change of Cdh1 mRNA levels
relative to Control-IEC-6 cells. The values are from three independent sample sets run in duplicate, normalized to TATA-binding protein (TBP),
pumilio RNA-binding family member 1 (Pum1) and ribosomal protein L19 (Rpl19) expression. The primer sequences are listed in Additional file 2.
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untransformed cells, IEC-6 cells ceased proliferation upon
the establishment of cell-cell contacts [5,25]. As such,
Control-IEC-6 cells formed a monolayer of well-organized
epithelial cells upon reaching confluence (Figure 2B). In
sharp contrast, each of the oncogenic transformed IEC-6
cell populations appeared highly disorganized and grew in
multiple layers at confluence (Figure 2B). Thus, oncogenic
specific activation of Grb2- or Shc-dependent signals per-
mits IECs to bypass contact inhibition of growth. To valid-
ate this in a quantitative manner, focus formation assays
were performed. As expected [5], Control-IEC-6 cells
failed to form foci, whereas TM-Grb2-IEC-6, TM-Shc1-
IEC-6, and TM-Shc2-IEC-6 cells displayed strong focus-
forming capacities, though less than that of Tpr-Met-IEC-
6 cells (Figure 2C and D). The number and size of foci
formed by the TM-Shc1-IEC-6 cells were markedly
greater than those of the TM-Grb2-IEC-6 or TM-Shc2-
IEC-6 cells (Figure 2C and D), likely reflecting their acce-
lerated growth rate (Figure 2A). These results indicate that
the oncogenic engagement of Grb2- and Shc-dependentsignals is sufficient to relieve contact inhibition of growth
in IECs.
Oncogenic engagement of Grb2 and Shc signaling
induces anchorage-independent growth and anoikis
resistance in IECs
We next verified whether the oncogenic activation of
Grb2- or Shc-dependent signals is sufficient to confer to
non-transformed IEC-6 cells the capacity to grow in the
absence of anchorage to the extra-cellular matrix (ECM),
by performing soft agar growth assays. Consistent with
previous findings [5], Control-IEC-6 cells failed to grow in
soft agar whereas Tpr-Met-IEC-6 cells grew efficiently,
forming numerous large colonies (Figure 3A–C). TM-
Grb2-IEC-6, TM-Shc1-IEC-6, and TM-Shc2-IEC-6 cells
also formed colonies in soft agar, but with lower efficien-
cies. While the three IEC-6 cell populations expressing
docking-specific Tpr-Met variants formed similar num-
bers of colonies (Figure 3A), those produced by the TM-
Shc1-IEC-6 cells were larger and displayed a different
morphology from those produced by the TM-Shc2-IEC-6
Figure 2 TM-Grb2, TM-Shc1 and TM-Shc2 oncoproteins elicit cell growth and loss of contact inhibition of growth in IEC-6 cells.
(A) Representative growth curves of IEC-6 cells expressing, or not (Control), the indicated Tpr-Met-derived oncoproteins. The doubling times calculated
in hours, from 3 independent experiments performed in triplicate, are for Tpr-Met-IEC-6: 15.4 ± 0.3; TM-Grb2-IEC-6: 21.5 ± 0.6; TM-Shc1-IEC-6: 18.3 ± 0.5;
TM-Shc2-IEC-6: 20.9 ± 0.7 and Control-IEC-6: 29.5 ± 1.9. (B) Photographs show typical morphology of the cells cultured at high density in the presence
of serum. (C) Focus formation assays were performed with the indicated IEC-6 cell populations. The bar graph shows the average number of
foci over ~10 days counted on stained plates in 3 independent experiments performed in triplicate. Values are expressed as percentage foci ±
S.E.M. of those formed by Tpr-Met-IEC-6 cells. (D) Photographs show representative morphology of the foci formed prior to formalin fixation
and after Giemsa staining (small insets).
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formed by the TM-Shc1-IEC-6 cells were composed mainly
of loosely associated cells with apparently limited cell-cell
contacts, similar to Tpr-Met-IEC-6 colonies (Figure 3B). By
contrast, colonies produced by the TM-Grb2-IEC-6 or
TM-Shc2-IEC-6 cells were compact and composed of
tightly associated cells (Figure 3B).
Growth in soft agar reflects not only the capacity of
cells to proliferate in the absence of ECM attachment,
but also to avoid anoikis, a form of apoptosis induced
upon loss of matrix attachment [32]. Anoikis assays were
performed by monitoring the viability of cells seeded in
the absence of serum under adherent and suspension con-
ditions. As expected for normal IECs [33,34], Control-
IEC-6 cells displayed anoikis sensitivity under suspension
culture conditions (Figure 3D). In contrast, IEC-6 cells
transformed by either Tpr-Met, or the Grb2 or Shc
docking-specific oncoproteins, displayed potent resist-
ance to anoikis, with more than half surviving under
non-adherent conditions. Likewise, the viability of these
transformed cells was significantly higher than that of
Control-IEC-6 cells when seeded in the absence of
serum and under adherent conditions (Figure 3E).
Overall, these results indicate that the oncogenicengagement of signals downstream of Grb2 or Shc is suffi-
cient to alleviate the anchorage-dependence of growth,
and to reduce sensitivity to growth factor deprivation and
to anoikis in IECs.
Silencing of Grb2 impairs Tpr-Met-induced morphological
transformation and anoikis resistance in IECs, but reduced
expression of Shc decreases cell growth
The above results with the docking-specific Tpr-Met-
derived variants established that the oncogenic activation
of either Grb2 or Shc signaling pathways was each suffi-
cient to promote transformation of IECs, conferring
upon them aberrant growth characteristics and resist-
ance to anoikis. We next sought to determine whether
signaling pathways downstream of these adaptor pro-
teins were required for the oncogenic potential of Met
in IECs. The impact of silencing the expression of Grb2
or Shc on the features of the Tpr-Met-IEC-6 cells was
evaluated. Stable populations of Tpr-Met-IEC-6 cells dis-
playing marked and selective knockdown of Grb2 (TM-
shGrb2) or Shc (TM-shShc) were generated using shRNAs.
As demonstrated by IB analyses (Figure 4A), Grb2 and Shc
(all ShcA isoforms) protein levels were selectively reduced
by more than 60% in TM-shGrb2 and TM-shShc cell
Figure 3 TM-Grb2, TM-Shc1 and TM-Shc2 oncoproteins induce anchorage-independent growth and anoikis resistance in IEC-6 cells.
(A) The ability of the indicated IEC-6 cell populations to grow in an anchorage-independent manner was tested in soft agar assays. The bar graph
represents the average number of colonies formed in soft agar, expressed as percentage ± S.E.M. of those produced by Tpr-Met-IEC-6 cells, from 3
independent experiments performed in triplicate. Tpr-Met-IEC-6 cells, when seeded at a density of 5000 cells in a 6-well plate, were producing an
average of 300–500 colonies after ~ 10 days. (B) Photographs depict typical morphology of the colonies formed in soft agar. (C) The bar graph
represents the average size of colonies formed in soft agar, expressed as percentage ± S.E.M. of those produced by Tpr-Met-IEC-6 cells, from 3
independent experiments performed in triplicate. (D) Anoikis sensitivity of these IEC-6 cell populations was tested. Cell viability was measured by
XTT assays 18 hours after seeding the cells in suspension or adherent conditions. The bar graph shows in percentage the mean ± S.E.M. value of
viable cells grown in suspension relative to the adherent ones, calculated from 4 independent experiments performed in triplicate. (E) Cell
viability in adherent condition, expressed as the percentage mean ± S.E.M. relative to Tpr-Met, is shown.
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cells expressing a non-targeting shRNA (TM-shCTRL).
Protein levels of Tpr-Met and actin remained equivalent
amongst all these cell populations. Phase contrast micros-
copy revealed that the TM-shGrb2 cells exhibited a partial
reversal of the transformed morphology, relative to TM-
shCTRL cells, characterized by a decrease in cell refractility
and an increase in cell spreading (Figure 4B). In contrast,
the TM-shShc cells maintained the transformed morph-
ology, and even adopted a slightly more elongated and
spindle-shaped appearance than the control TM-shCTRLcells. Concordant with these morphological changes,
E-cadherin protein levels were enhanced in TM-shGrb2
cells and reduced in TM-shShc cells, when compared
to TM-shCTRL cells (Figure 4C and D).
Growth and survival characteristics of these cells were
then evaluated in cell-count and anoikis assays, respect-
ively. While the TM-shGrb2 cells displayed similar growth
capacity to TM-shCTRL cells, growth of the TM-shShc
cells was observed to decrease in a time-dependent man-
ner, reaching significant inhibition (37.67 ± 5.32%) 3 days
after seeding (Figure 4E). The TM-shGrb2 cells displayed
Figure 4 Silencing of Grb2 in Tpr-Met-IEC-6 cells restores an epithelioid morphology, E-cadherin expression and anoikis sensitivity,
while Shc knockdown decreases cell growth. (A) Protein levels of Grb2, Shc and Tpr-Met were assessed by IB analyses of lysates of serum
starved Tpr-Met-IEC-6 cell populations stably expressing shRNA against Grb2 (TM-shGrb2) or Shc (TM-shShc), or a control non-targeting shRNA
(TM-shCTRL). Densitometry analyses of IB revealed close to 60% reduction in Grb2 and Shc protein levels in TM-shGrb2 and TM-shShc cells,
respectively, when compared to TM-shCTRL. (B) Photographs show typical morphology of the indicated shRNA-expressing Tpr-Met-IEC-6 cells
when cultured in the presence of serum at either low or high density. (C) E-cadherin protein levels were determined by IB analyses in lysates of
serum-starved cells. (D) Densitometric analysis of E-cadherin protein levels normalized to actin was performed. The bar graph shows the mean ±
S.D. fold-change relative to TM-shCTRL cells calculated from at least 3 independent experiments. (E) Cell-count assays were performed at the
indicated time after seeding the cells under adherent culture conditions and in presence of serum. Bar graph shows the mean number of cells ±
S.E.M., from 3 independent experiments performed in triplicate. (F) Anoikis sensitivity of the indicated cell populations was evaluated. Cell viability
was measured by XTT assays 18 hours after seeding the cells in suspension or adherent conditions. The bar graph shows in percentage the mean ±
S.E.M. cell viability in suspension relative to in adherent state, normalized to TM-shCTRL cells calculated from 3 independent experiments performed in
triplicate. (G) The bar graph shows in percentage the mean ± S.E.M. of cell viability in adherent condition expressed relative to Tpr-Met.
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shCTRL and TM-shShc cells, between which no difference
in survival in suspension was observed (Figure 4F). As
shown in Figure 4G, no significant difference in cell viability
was observed between the TM-shGrb2, TM-shShc, and
TM-shCTRL cells 18 hours following seeding in the ab-
sence of serum under adherent conditions (Figure 4G). To-
gether, these results suggest that signals downstream of
Grb2 and Shc proteins are required for non-overlapping
functions promoted by the oncogenic Met receptor in IECs.
MEK, but not PI3K inhibitors reduce IEC transformation
promoted by the oncogenic engagement of Met, Grb2, or
Shc signals
The Grb2 and Shc adaptor proteins are known to couple
RTKs, such as the Met receptor, to the Ras/MAPK andPI3K/Akt signaling pathways [28-30]. The Ras/MAPK
and PI3K/Akt pathways are important regulators of
RTK-mediated epithelial cell transformation, but their
actions are cell type-specific [31]. To define the role of
these signaling pathways in IEC transformation, we first
compared their activation status in IEC-6 cells transformed
by the Tpr-Met, TM-Grb2, TM-Shc1, and TM-Shc2 onco-
proteins, to that one in non-transformed Control-IEC-6
cells. The phosphorylation/activation levels of the down-
stream effectors of MEK and PI3K, Erk1/2 and Akt, re-
spectively, were assessed by IB analyses of lysates prepared
from serum-starved IEC-6 cells. Phosphorylation levels of
neither Erk1/2 nor Akt were elevated in Tpr-Met-IEC-6,
TM-Grb2-IEC-6, TM-Shc1-IEC-6, or TM-Shc2-IEC-6 cells,
relative to Control-IEC-6 cells (Figure 5A). Both Erk2 and
Akt protein levels were comparable in all IEC-6 cell
Figure 5 Inhibitors of MEK1/2, but not of PI3K, inhibits morphological transformation and restores E-cadherin expression in IEC-6 cells
transformed by Tpr-Met, TM-Grb2, TM-Shc1 and TM-Shc2 oncoproteins. (A) Basal phosphorylation and expression levels of Erk1/2 and Akt
were assessed by IB analyses of TCL prepared from the indicated serum-starved IEC-6 cells. (B) The indicated cells were treated with vehicle
(DMSO), or 10 μM of MEK1/2 and/or PI3K inhibitors. Photographs show typical morphologies following 48 hours of treatment. Similar morphological
changes were observed after 24 hours of treatment (Additional file 3). (C) E-cadherin and actin protein levels were assessed by IB analysis after 48 hours
of treatments with DMSO or the indicated inhibitors. (D) Relative E-cadherin and actin protein levels were determined by densitometry analysis. The
bar graph shows the mean ± S.D. fold-changes in E-cadherin protein levels normalized to that of actin relative to DMSO treated cells. The values were
calculated from at least three independent experiments. (E) The MEK1/2 and PI3K inhibitors were validated to selectively block serum-induced Erk1/2
and Akt phosphorylation in Tpr-Met-IEC-6 and Control-IEC-6 cells. Serum-starved cells were treated for 1 hour with DMSO or indicated inhibitors, prior
to 5 minutes of stimulation with 10% serum. Erk1/2 and Akt phosphorylation and total protein levels were heaevaluated as above. Actin levels were
used as a loading control. The results are representative of at least 2 independent experiments.
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lation was observed in cells maintained in the presence of
serum (data not shown). The lack of evidence for Erk1/2
and Akt activation in IEC-6 cells stably expressing the con-
stitutively activated form of the Met receptor, or the Grb2
and Shc docking-specific oncoproteins, is consistent with
both the Ras/MAPK and PI3K/Akt pathways being subject
to negative feedback mechanisms [35]. It cannot be ex-
plained as merely a cell type–specific event, since similarlystable expression of these oncoproteins in fibroblasts failed
to promote Erk1/2 or Akt activation [36 and unpublished
observation].
We next investigated whether, even at the low levels
observed, MEK or PI3K activities were implicated in the
induction of transformation features in IEC-6 cells by
the Tpr-Met, TM-Grb2, TM-Shc1, or TM-Shc2 oncopro-
teins. Cells were treated with vehicle (DMSO), 10 μM
U0126 (a MEK1/2 inhibitor), 10 μM LY294002 (a PI3K
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morphology was examined by phase contrast micros-
copy, following 24 (Additional file 3) and 48 hours of
treatment (Figure 5B). Neither individual inhibitor treat-
ment, nor the combination, had an obvious effect on the
morphology of the Control-IEC-6 cells. Interestingly, the
MEK1/2 inhibitor, but not the PI3K inhibitor, induced a
potent reversion of the transformed morphological fea-
tures of the Tpr-Met-IEC-6, TM-Grb2-IEC-6, TM-Shc1-
IEC-6, and TM-Shc2-IEC-6 cells, observed within
24 hours of treatment (Additional file 3) and more strik-
ing in appearance after 48 hours (Figure 5B). In the
presence of U0126, the MEK1/2 inhibitor, either alone
or in combination with the PI3K inhibitor, the formerly
transformed Tpr-IEC-6 cells progressively lost their
fibroblast-like spindle-shaped morphology, adopted a
flatter cobblestone-like appearance, reformed apparent
cell-cell contacts and grew again in colonies; much like
the non-transformed Control-IEC-6 cells.
Concordant with this restoration of epithelioid-like mor-
phological features in IEC-6 cells transformed by the
oncogenic Tpr-Met and its derived variants, treatment
with U0126 also induced an increase in E-cadherin protein
levels (Figure 5C and D, and Additional file 3). By contrast,
none of the inhibitor treatments affected E-cadherin pro-
tein levels in the Control-IEC-6 cells (Figure 5C and D).
Notably, reversion of the transformed phenotype and E-
cadherin up-regulation were also promoted in trans-
formed IEC-6 cell populations by treatment with 10 μM
AZD6244 or PD184352, two additional pharmacological
inhibitors of MEK1/2 (Figure 5B and C, and Additional
file 3). Furthermore, these observations could not be at-
tributed to the cytosolic localization of the Tpr-Met onco-
protein, since both the morphological transformation and
the E-cadherin down-regulation induced by a cell surface-
localized active chimeric colony stimulating factor 1
(CSF)-Met receptor [37], were reverted in a similar man-
ner upon the inhibition of MEK1/2 activity, but not of
PI3K activity (Additional file 3).
Since Erk1/2 and Akt activities remained at basal
levels in transformed IEC-6 cell populations, the efficacy
of these pharmacological inhibitors was evaluated by
testing their ability to suppress serum-induced Erk1/2
and Akt phosphorylation. Serum-starved Tpr-Met and
control IEC-6 cell populations were treated for 1 hour
with DMSO or inhibitors, followed by 5 minutes of
stimulation with 10% serum. A robust phosphorylation
of Erk1/2 and Akt proteins was seen upon serum stimu-
lation of Control-IEC-6 cells (Figure 5E). In sharp con-
trast, although the levels of Erk2 and Akt proteins were
equivalent for each cell population, serum-induced
Erk1/2 and Akt activation were severely attenuated in
the Tpr-Met-IEC-6 cells (Figure 5E). This further sub-
stantiates the conclusion that sustained activation ofMet signaling pathways, such as those downstream of
Grb2 and Shc, can activate negative feedback control of
both the Erk1/2 and Akt pathways in IECs. Importantly,
the MEK1/2 and PI3K inhibitors were confirmed to effi-
ciently suppress serum-induced Erk1/2 and Akt phos-
phorylation, respectively (Figure 5E). Although the
potential off-target effects of these inhibitors cannot be
excluded in these experiments, our results suggest that
the morphological transformation induced by the onco-
genic Met receptor, and driven by the constitutive acti-
vation of Grb2 and Shc signals in IECs, relies, at least in
part, on the activation of the Ras/MAPK pathway, but
not on PI3K signaling.
The growth promoting effect of oncogenic Met in IECs is
blocked by MEK inhibition, but anoikis sensitivity is
restored by concomitant treatment with MEK and PI3K
inhibitors
We next investigated whether the growth capacity pro-
moted by the oncogenic Met in IECs required MEK or
PI3K activity. Cell-count assays were performed with
Tpr-Met and Control-IEC-6 cells that were treated for
24 or 48 hours with vehicle, U0126 or LY294002 inhibi-
tor, or a combination of both inhibitors. As anticipated,
treatment with DMSO did not significantly impact cell
growth, even after 48 hours. Treatment with LY294002
exerted similar inhibitory effects upon the growth of both
the Tpr-Met-transformed and control IEC-6 cells, redu-
cing the number of cells by 44% and 36%, respectively
relative to DMSO-treated cells, after 48 hours (Figure 6A).
In contrast, in the presence of U0126, the growth of Tpr-
Met-IEC-6 cells was significantly attenuated but not that
of Control-IEC-6 cells (Figure 6A). Furthermore, while
co-treatment with U0126 failed to potentiate the growth
inhibiting effect of LY294002 in Control-IEC-6 cells, the
growth of Tpr-Met-IEC-6 cells was further reduced in a
time-dependent manner upon exposure to both inhibitors
(Figure 6A).
The impact of inhibiting MEK1/2 or PI3K activity on
the viability of Tpr-Met-IEC-6 cells in suspension was
also evaluated. In these anoikis assays, vehicle or the in-
dicated inhibitors were added when cells were seeded
and cell viability was measured 24 and 48 hours later.
Treatment with the PI3K inhibitor restored anoikis sen-
sitivity to the Tpr-Met-IEC-6 cells in a time-dependent
manner, reducing their viability by close to 45% relative
to DMSO-treated cells after 48 hours (Figure 6B). The
MEK1/2 inhibitor, on the other hand, did not substan-
tially impact the viability of the Tpr-Met-IEC-6 cells
grown in suspension. Nonetheless, U0126 treatment did
elicit a marked synergistic effect on LY294002-induced
anoikis, reducing Tpr-Met-IEC-6 cell viability to levels
well below those seen upon treatment with the PI3K in-
hibitor alone (Figure 6B). These results suggest that Tpr-
Figure 6 Tpr-Met-mediated enhanced growth in IECs is reduced by inactivation of MEK1/2, and resistance to anoikis is restored by
dual inactivation of MEK1/2 and PI3K. (A) Cell-count assays were performed with Tpr-Met and Control-IEC-6 cells cultured under adherent
conditions and in presence of serum, after 24 and 48 hours of treatment with vehicle (DMSO), 10 μM of the MEK1/2 or PI3K inhibitor, or a
combination of both inhibitors. The bar graph shows as percentage the mean number of cells ± S.E.M. relative to DMSO-treated cells. (B) Anoikis
assays were conducted 24 and 48 hours after seeding Tpr-Met-IEC-6 cells in suspension, and concurrently in the presence of the vehicle or
indicated inhibitors. The bar graph represents in percentage the mean value ± S.E.M. of cell viability normalized to DMSO-treated cells, calculated
from 3 independent experiments performed in triplicate.
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IECs implicate MEK-dependent mechanisms, but that
the anoikis resistance involves the integration of both
MEK- and PI3K-dependent signaling pathways.
Discussion
As normal intestinal epithelial cells become cancerous,
they gain the ability to grow aberrantly by evading normal
growth-inhibiting and death signals, as well as the ability
to invade tissue [38]. Experimental and clinical studies
suggest that the deregulation of RTKs plays a critical role
in the etiology and progression of human CRC [2-4].
These studies highlight the ability of RTKs to induce bio-
logical characteristics linked with tumorigenesis and meta-
static progression [1,38]. However, the proximal signaling
molecules recruited by RTKs have not yet been assigned
individual contributions to the neoplastic transformation
of normal IECs. In this study, Met-derived docking-
specific variants were used to define the cancer properties
induced upon the RTK-mediated engagement of the Grb2
or Shc adaptor proteins in IECs. Our results show, for the
first time in a non-transformed IEC model, that the sus-
tained activation of signals downstream of either Grb2 or
Shc alone is sufficient to promote morphological trans-
formation, E-cadherin down-regulation, enhanced cell
growth, loss of contact inhibition of growth, the acquisi-
tion of anchorage-independence of growth, and anoikis re-
sistance (Figures 1, 2, 3). These oncogenic features are
prerequisites for the progression of epithelial-derived can-
cers, favoring the survival and growth of cancerous cells
in the matrix-poor, disorganized extracellular environ-
ments often found in primary tumors, and in systemic cir-
culation, facilitating metastasis [32,38]. Thus, our results
provide novel evidence for a causal role of RTK-linked
Grb2 and Shc signaling pathways in important and com-
mon phenotypic features of neoplastic transformation of
IECs and metastatic CRCs.Expression of the cell adhesion molecule, E-cadherin,
is typically depleted from cell-cell contacts in epithelial
cancer cells, or even shut down altogether [31]. Cellular
loss of E-cadherin leads to dissolution of adherens junc-
tions and to a reduction in cell-cell contacts, facilitating
migration and invasion, both of which are key processes
for metastatic dissemination of epithelial tumor cells. Not-
ably, an inverse correlation exists between E-cadherin levels
in human CRC specimens and cancer grade, invasiveness
of tumor phenotype, metastatic disease progression, and
poor patient prognosis [39]. Multiple mechanisms have
been identified that promote E-cadherin down-regulation
in epithelial cells, in response to different stimuli and/or in
different cell types. These include transcriptional silencing
via deregulation of transcription factors (Snail, Twist, and
Zeb) or promoter hyper-methylation, and internalization
followed by subsequent lysosomal degradation mediated by
post-translational modifications [31,40]. E-cadherin protein
levels were further reduced in IEC-6 cells expressing the
Shc docking-specific oncoproteins than those transformed
by TM-Grb2 or Tpr-Met (Figure 1). Differential expression
levels of these oncoproteins cannot fully account for this
response, therefore suggesting that Grb2 and Shc might
mediate E-cadherin down-regulation by distinct mecha-
nisms. However, E-cadherin levels and an epithelial
non-transformed typical morphology were restored
upon pharmacological inhibition of MEK1/2 but not of
PI3K, activities in IECs transformed by these oncopro-
teins (Figure 5 and Additional file 3). These findings
suggest that the engagement of Grb2 and Shc, like Met,
promotes these oncogenic features through shared sig-
naling pathways. Furthermore, E-cadherin repression
induced by oncogenic Met signaling pathways in IECs,
like that driven by Grb2 and Shc, was associated with
an up-regulation of the repressors of E-cadherin tran-
scription Snail2, Twist1, or Twist2, but not of Snail1 or
Zeb1 (Additional file 2). Future studies will be needed
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sult in E-cadherin down-regulation in IECs downstream
of Grb2 or Shc. Nonetheless, our results suggest that
these adaptor proteins are important integrators of sig-
nals leading to the neoplastic transformation and E-
cadherin dysfunction in CRC harboring the deregulated
Met receptor, and most likely other RTKs.
A role for deregulated RTKs in conferring anoikis re-
sistance to IECs through cross-talk with cell adhesion
receptors, is well-established [32]. While transforming
growth factor-α (TGF-α) stimulation protects IECs from
anoikis [41], CRC cells that express high levels of EGF/
TGF-α evade anoikis through autocrine stimulation of
the EGFR [33]. However, the importance of Grb2 or Shc
functions in anoikis resistance in IECs has not been ad-
dressed. Furthermore, of the very few investigations of
the HGF/Met receptor axis in anoikis control and can-
cer, a single study has reported a key role for the Met re-
ceptor in CRC cells [42]. Activation of the Met receptor
has been reported to prevent anoikis in human colon,
ovarian, pancreatic, and head and neck carcinoma cell
lines by mechanisms dependent on PI3K, but with varied
requirement for MEK1/2 [42-45]. Herein, we have shown
that while individual inhibition of PI3K activity, but not of
MEK1/2, partially restored anoikis sensitivity in Tpr-Met-
IEC-6 cells, concurrent inhibition of these pathways
exerted a synergistic effect (Figure 6). Notably, anoikis re-
sistance driven by the oncogenic Met receptor in IECs is
partly dependent on Grb2 functions, whereas Shc func-
tions appear dispensable (Figure 4). Our findings suggest a
model whereby deregulation of Met might promote anoi-
kis resistance in CRC cells, through the integration of both
MEK and PI3K signaling pathways, and likely involving
the engagement of Grb2. Collectively, our results provide
novel evidence that signaling pathways engaged by
deregulated RTKs in CRC, including those reliant on
Grb2 or Shc, may represent important regulators of anoi-
kis resistance in IECs, a process of outmost relevance in
cancer metastasis.
We show that oncogenic Met receptor-dependent sig-
nals, like those activated downstream of Grb2 and Shc,
trigger negative feedback upon the Ras/MAPK and
PI3K/Akt pathways in IECs, restricting Erk and Akt acti-
vation (Figure 5 and Additional file 3). Although some-
what controversial, some studies suggest that Erk
hyperactivation may only occur in a small subset of CRC
tumors, and that Erk activity is more often elevated in
adjacent normal tissue [46-48]. Also, Erk activity in hu-
man CRC tumors appears to be a poor predictor of acti-
vating K-RAS mutation status and of the effectiveness of
MEK inhibition [48-50]. We report the inhibition of the
IEC transformation and E-cadherin down-regulation in-
duced by each of our oncoproteins by inhibitors of MEK
activity, but not of PI3K activity (Figure 5 and Additionalfile 3). Cell growth and anoikis resistance evoked by
Tpr-Met, on the other hand, was blocked by concomi-
tant treatment with MEK and PI3K inhibitors (Figure 6).
Thus, our findings suggest that while growth factor
stimulation is linked to the activation of the Ras/MAPK
and PI3K/Akt pathways, in part through Grb2 and Shc,
Erk or Akt activity levels in CRC may not reliably pre-
dict the extent of RTK deregulation, nor the sensitivity
to therapies targeting them.
The Tpr-Met and the Grb2- and Shc-specific docking
oncoproteins are all predicted to promote cancer fea-
tures in IECs by engaging similar signaling pathways.
Indeed, they share the ability to complex with the Gab1
scaffolding protein. While binding to TM-Grb2 and
TM-Shc oncoproteins by Grb2-dependent mechanisms,
Gab1 also interacts directly with the Met receptor
[8,20,51]. Notably, Gab1 has been shown to be required
for Erk and Akt activation, and many oncogenic functions
downstream of Met, and the Grb2- and Shc-docking
oncoproteins in fibroblast, MDCK epithelial, and Xenopus
cell models [20,28]. Thus, it may be that Gab1 provides a
platform for the integration of Ras/MAPK and PI3K/Akt
positive and negative signals downstream of these onco-
proteins and relevant to their oncogenic functions in IECs.
However, Tpr-Met-IEC-6 cells were observed to display
stronger transformed phenotypes than cells expressing the
Grb2 or Shc-binding variants oncoproteins, for example
in focus-formation and growth in soft agar (Figures 2
and 3). This suggests that Tpr-Met may activate path-
ways not engaged by the Tpr-Met Shc or Tpr-Met Grb2
oncoproteins. Furthermore, it is now acknowledged
that Shc, by interacting with proteins other than Grb2
such as IQGAP1, Crk and Sgk269, can promote Grb2-
independent pathways and functions [13,17-19], under-
scoring the complexity of the cellular networks that
these adaptor proteins can engage downstream of
RTKs. It is therefore anticipated that the Grb2- and
Shc-specific docking oncoproteins, and Tpr-Met may
prove, upon further analyses, to mediate distinct signa-
ling pathways, and therefore specific cancer processes
in IECs.
Therapies targeting RTKs are recognized as a promis-
ing avenue for the treatment of cancer, but the clinical
benefits observed with these agents have so far been
modest. As typified by EGFR-targeted therapies for
metastatic CRC (e.g.: panitumumab and cetuximab), this
modest response is attributed to the innate and acquired
proficiency of cancer cells to escape EGFR inhibition by
engaging alternative oncogenic signals [2,3,52]. Multiple
mechanisms of resistance have been proposed, including
the manifest heterogeneity of RTKs being deregulated in
CRC cells [52,53]. Notably, activation of the Met/HGF
receptor axis is emerging as an important mechanism of
resistance to drugs targeting oncogenic kinases in
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ition of multiple RTKs in CRC cells seems to offer better
therapeutic effects than targeting a specific RTK [53-60].
An alternative way to achieve similar outcomes might be
offered by targeting RTK-proximal signaling effectors
engaged by all, or at least several RTKs, particularly
those regulating biological processes critical for the initi-
ation and/or progression of CRCs. In this regard, we show
that although oncogenic engagement of Grb2 or Shc trig-
gers redundant cancer properties in IECs (Figures 1, 2, 3),
these adaptor proteins were proven, through analysis of
the impact of their silencing in Tpr-Met-transformed
IECs, to be necessary for non-overlapping functions
(Figure 4). The silencing of Shc in Tpr-Met-IEC-6 cells
was demonstrated to partly reduce cell growth without
impacting anoikis resistance, but slightly increasing
transformation and E-cadherin down-regulation. These
results indicate that the Met receptor has the intrinsic
capacity to circumvent the loss of Shc functions by en-
gaging alternative oncogenic signals, likely involving
the adaptor proteins Grb2, Gab1, or others effectors.
Conversely, inhibition of Grb2 functions restored nor-
mal non-transformed epithelial morphology, E-cadherin
expression, and anoikis sensitivity in these same Met-
transformed IECs. Incidentally, Grb2 SH2 domain-binding
antagonists were shown in vitro to block HGF-induced
migration and invasion in MDCK epithelial cells, metasta-
sis formation of melanoma and prostate cancer cells
in vivo, and the motility of human SW620 CRC cells in
wound-healing in vitro assays [61-63]. Considering these
observations, with our current findings, we suggest the
targeting of Grb2 signaling in CRC, particularly in the
context of deregulated Met, as a potentially effective thera-
peutic strategy to reduce CRC metastasis.
Conclusions
The design of novel CRC therapies is contingent on a
better understanding of the mechanisms underlying the
ability of deregulated RTKs to relay downstream signa-
ling pathways that convey oncogenic properties in
normal IECs. In this study, we provide evidence that
Met-driven oncogenic activation of Grb2 or Shc signa-
ling leads to the neoplastic transformation of normal
IECs and induces multiple redundant hallmarks of can-
cer in these cells. Sustained engagement of Grb2 and
Shc in IECs was also identified to evoke negative feed-
back control of the Ras/MAPK and PI3K/Akt pathways,
limiting their degree of activation, however these path-
ways seem to remain critical to oncogenic functions.
Notably, our data also illustrate the functional non-
redundancy of Grb2 and Shc downstream of Met, and
suggest that Grb2 might represent a promising target
for the design of novel therapies for CRC harboring
deregulated Met, and possibly other RTKs.Additional files
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